Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Acq. announced
Quarterly results
Auditor change
Appointed director
CC transcript
Director departure
|
|
SEELOS THERAPEUTICS, INC. (APRI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/29/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/29/2023 |
8-K
| Other Events Interactive Data |
| 05/19/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2023",
"Amendment No. 3 to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC",
"Form of Warrant",
"Form of Amendment No. 1 to Securities Purchase Agreement, by and between Seelos Therapeutics, Inc. and each purchaser identified on the signature pages thereto" |
|
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/24/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/14/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: March 14, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           ...",
"COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: September 14, 2023 Issue Date: March 14, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 14, 2023 and on or prior to 5:00 p.m. on September 14, 2028 but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .        ̷...",
"Brownstein Hyatt Farber Schreck, LLP",
"300 Park Avenue, 2nd Floor",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 10, 2023, between Seelos Therapeutics, Inc., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchase..." |
|
| 03/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/10/2023 |
8-K
| Investor presentation |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 4.7% stake in Seelos Therapeutics Inc. |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/01/2022 |
8-K
| Other Events Interactive Data |
| 08/05/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/22/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 04/12/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/11/2022 |
8-K
| Acquisition/merger/asset purchase announced |
| 03/04/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/10/2022 |
SC 13G/A
| VANGUARD GROUP INC reports a 5% stake in Seelos Therapeutics Inc. |
| 02/04/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/18/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/10/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/28/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/27/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/13/2021 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|
|
|